ACHP

Key Product Details

Product Description

ACHP is a IκB kinase inhibitor (IC₅₀ values are 8.5 and 250 nM for IKKβ and IKKα respectively). Selective for IKKα and IKKβ over IKK3, Syk and MAPKKK4 (IC₅₀ values are > 20 μM). Inhibits DNA binding activity of NF-κB. Blocks NF-κB pathway in multiple myeloma cell lines; induces cell growth arrest and apoptosis. Also inhibits STAT3 signaling in NSCLC in vitro.

Product Specifications for ACHP

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ACHP

The following data is based on the product molecular weight 364.44.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	13.72 mL	68.60 mL	137.20 mL
1 mM	2.74 mL	13.72 mL	27.44 mL
2 mM	1.37 mL	6.86 mL	13.72 mL
10 mM	0.27 mL	1.37 mL	2.74 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 31 publications citing the usage of this product.

• Murata Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg.Med.Chem.Lett. 2004 PMID: 15225718
• Lee The IκB kinase inhibitor ACHP targets the STAT3 signaling pathway in human non-small cell lung carcinoma cells. Biomolecules 2019 PMID: 31847229
• Sanda Growth inhibition of multiple myeloma cells by a novel IκB kinase inhibitor. Clin.Cancer Res. 2005 PMID: 15756023

Product Documents for ACHP